Growth hormone peptides tesamorelin

The case for tesamorelin rests on something most research peptides lack: two well-controlled Phase III trials showing sustained visceral fat reduction in humans. That clinical evidence, combined with FDA approval for HIV-associated lipodystrophy, makes it the rare GHRH analog with documented efficacy outside rodent models. The limitation is specificity — tesamorelin targets one pathology (antiretroviral-induced fat accumulation) rather than general body composition or anti-aging claims that dominate the peptide community.

Why Tesamorelin Is a Modified Growth Hormone-Releasing Hormone, Not Growth Hormone Itself

Tesamorelin is a synthetic 44-amino-acid peptide that replicates the first 44 residues of endogenous human growth hormone-releasing hormone (GHRH), with a single modification: a trans-3-hexenoic acid group attached to the N-terminus. That lipid modification extends the peptide's half-life in circulation, slowing enzymatic degradation while preserving receptor binding affinity.

Natural GHRH is a 44-residue hypothalamic peptide that stimulates pituitary growth hormone release through the GHRH receptor (GHRHR). The body produces GHRH in pulsatile bursts, which drive corresponding pulses of GH secretion. Pharmaceutical development of GHRH analogs like tesamorelin began in the 1980s, when researchers observed that direct GH administration carried metabolic side effects that GHRH-driven endogenous secretion might avoid.

Theratechnologies developed tesamorelin specifically for HIV-associated lipodystrophy — a side effect of long-term antiretroviral therapy marked by visceral fat accumulation, particularly in the abdomen. The compound received FDA approval in 2010 under the trade name Egrifta, making it one of the few GHRH analogs with regulatory clearance for clinical use. Unlike Sermorelin, which is also a GHRH analog but lacks the hexenoic acid modification, tesamorelin's structure was optimized for stability in the context of sustained visceral adipose tissue (VAT) reduction.

How Tesamorelin Activates the GHRH Receptor to Drive Pulsatile Growth Hormone Secretion

Tesamorelin binds the growth hormone-releasing hormone receptor (GHRHR), a G-protein-coupled receptor expressed on somatotroph cells in the anterior pituitary gland. GHRHR is a class B GPCR that couples to the Gs alpha subunit. Upon ligand binding, Gs alpha activates adenylyl cyclase, which catalyzes the conversion of ATP to cyclic AMP (cAMP).

Elevated intracellular cAMP activates protein kinase A (PKA), which phosphorylates downstream effectors that promote GH gene transcription and vesicle fusion. The result is release of endogenous growth hormone from pituitary stores into systemic circulation. This mechanism differs fundamentally from exogenous GH administration: tesamorelin preserves the pulsatile secretion pattern that defines normal GH physiology, while direct GH injections bypass that pulsatility entirely.

Once released, GH binds growth hormone receptors in peripheral tissues — particularly the liver — stimulating synthesis and secretion of insulin-like growth factor 1 (IGF-1). IGF-1 mediates many of GH's anabolic and metabolic effects, including lipolysis in adipose tissue. In the context of HIV lipodystrophy, elevated IGF-1 appears to preferentially mobilize visceral fat over subcutaneous fat, though the mechanism behind this selectivity remains incompletely characterized.

One functional advantage of tesamorelin over direct GH administration is preservation of negative feedback loops. Endogenous somatostatin, released from the hypothalamus in response to elevated GH and IGF-1, continues to regulate pulsatile secretion. This maintains homeostatic control over GH-IGF-1 signaling, potentially reducing the risk of hyperglycemia and other metabolic derangements associated with sustained supraphysiologic GH exposure.

Two Pivotal Trials Showed Durable Visceral Fat Reduction in HIV-Positive Adults

The strongest human evidence for tesamorelin comes from two randomized, double-blind, placebo-controlled Phase III trials published in 2010: ACTG 5260 and ACTG 5257. Both trials enrolled HIV-positive adults with abdominal fat accumulation on stable antiretroviral therapy. Together, they randomized over 800 participants to 2 mg subcutaneous tesamorelin daily versus placebo for 26 weeks.

The primary endpoint was percent change in visceral adipose tissue (VAT) area measured by CT scan at the L4-L5 vertebral level. In both trials, tesamorelin-treated participants showed a mean VAT reduction of approximately 15–18% from baseline, compared to minimal change in placebo groups. Changes were detectable within 12 weeks and plateaued by week 26. Subcutaneous adipose tissue showed minimal reduction, reinforcing the idea that the effect was anatomically selective for visceral depots.

Secondary endpoints included changes in IGF-1 levels, which increased significantly in tesamorelin arms — an expected pharmacodynamic marker of GHRH receptor activation and pituitary GH release. Waist circumference decreased modestly but consistently in treated groups. Adverse events were generally mild: injection site reactions occurred more frequently with tesamorelin than placebo, and glucose metabolism showed small but measurable perturbations, with a modest increase in hemoglobin A1c levels.

A 26-week extension study assessed durability. Participants who continued tesamorelin maintained VAT reductions through week 52, while those who discontinued returned toward baseline VAT levels within 26 weeks of stopping treatment. This reversibility underscores that tesamorelin does not permanently alter adipocyte physiology — it requires ongoing signaling to sustain lipolytic effects.

No comparable placebo-controlled human data exists for non-HIV populations. Case series and open-label studies have explored tesamorelin in metabolic syndrome and non-alcoholic fatty liver disease (NAFLD), but these lack the rigor of the HIV lipodystrophy trials. Rodent studies suggest GHRH analogs reduce hepatic steatosis and improve insulin sensitivity in diet-induced obesity models, but extrapolation to human metabolic disease outside HIV remains speculative as of 2026.

Research Dosing, Administration, and Half-Life from Published Protocols

The FDA-approved dose for tesamorelin is 2 mg administered subcutaneously once daily, typically in the abdominal region. This dose was selected based on Phase II dose-ranging studies that compared 1 mg, 2 mg, and 3 mg daily. The 2 mg dose produced the maximal VAT reduction with acceptable tolerability; higher doses increased side effects without proportional efficacy gains.

Tesamorelin is supplied as a lyophilized powder requiring reconstitution with sterile water prior to injection. Once reconstituted, the solution must be refrigerated and used within a short window — typically 3-7 days — due to peptide instability in aqueous solution. The hexenoic acid modification extends the peptide's serum half-life to approximately 26–38 minutes, compared to 7–12 minutes for unmodified GHRH. That short half-life reflects rapid enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4) and other peptidases, despite the N-terminal modification. For research purposes only, this half-life informs once-daily dosing protocols rather than multiple daily injections.

Peak GH secretion occurs within 30–60 minutes of subcutaneous administration, with IGF-1 levels rising more gradually over 2–4 hours and remaining elevated for up to 12 hours. This pharmacokinetic profile supports evening administration to align with the natural nocturnal GH pulse, though the pivotal trials did not specify time-of-day dosing.

Tesamorelin does not meaningfully interact with most antiretroviral agents, but it does affect glucose metabolism through IGF-1-mediated effects on insulin sensitivity. Monitoring fasting glucose and hemoglobin A1c is recommended in protocols extending beyond 26 weeks. Contraindications include active malignancy (due to theoretical concerns about GH/IGF-1-driven tumor growth), disruption of the hypothalamic-pituitary axis, and pregnancy.

One notable difference from Ipamorelin and other growth hormone secretagogues (GHRPs) is that tesamorelin acts upstream at the GHRH receptor rather than the ghrelin receptor. This limits additive or synergistic effects when co-administered with GHRPs, though some protocols have combined GHRH analogs with GHRPs to amplify GH pulse amplitude.

FAQ

Q: What distinguishes tesamorelin from sermorelin or CJC-1295?

All three are GHRH analogs, but tesamorelin has the trans-3-hexenoic acid modification for extended half-life (26–38 minutes vs. 7–12 minutes for sermorelin). CJC-1295 DAC uses a drug affinity complex to extend half-life even further (6–8 days). Tesamorelin is the only one with FDA approval and Phase III human data demonstrating visceral fat reduction.

Q: Does tesamorelin increase lean mass or just reduce fat?

In the HIV lipodystrophy trials, lean mass showed small but statistically insignificant increases — the primary measured effect was VAT reduction. This differs from direct GH administration, which typically produces more robust lean mass gains. The effect is selective for visceral fat mobilization rather than broad anabolic signaling.

Q: Can tesamorelin be used outside HIV lipodystrophy?

Off-label use occurs in research contexts for metabolic syndrome and NAFLD, but no placebo-controlled data exists in non-HIV populations. Open-label studies suggest potential efficacy in reducing liver fat and improving glucose tolerance, but these findings require replication in controlled trials.

Q: What are the main safety concerns with long-term tesamorelin use?

The most common adverse events are injection site reactions and mild increases in hemoglobin A1c, suggesting small perturbations in glucose metabolism. Theoretical concerns include IGF-1-driven tumor growth in patients with occult malignancies, which is why active cancer is a contraindication. Long-term cardiovascular or endocrine outcomes beyond 52 weeks remain incompletely characterized.

Q: How does tesamorelin compare to direct growth hormone injections?

Tesamorelin preserves pulsatile GH secretion and feedback regulation through endogenous somatostatin, which may reduce metabolic side effects like hyperglycemia. Direct GH produces more predictable IGF-1 elevations and greater lean mass gains, but bypasses physiologic feedback loops. The choice depends on whether the goal is selective VAT reduction or broader anabolic effects.

Statements on this page have not been evaluated by the Food and Drug Administration. Tesamorelin is not approved for use outside HIV-associated lipodystrophy and is not intended to diagnose, treat, cure, or prevent any disease.